MIRM News and Press, Mirum Pharmaceuticals Inc. From 03/25/24

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointme...

2024-03-18 16:15:01 ET Leerink Partners analyst issues BUY recommendation for MIRM on March 18, 2024 03:00PM ET. The previous analyst recommendation was Buy. MIRM was trading at $26.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...

2024-03-14 06:35:02 ET Mirum Pharmaceuticals ( NASDAQ: MIRM ) shares climbed over 9% premarket on Thursday as the U.S. FDA cleared the company’s Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with...

2024-03-14 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo - Label covers broad range of PFIC subtypes - Immediate launch and availability for eligible patients in the U.S. ...

- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p<0.0001) - Data are the first to demonstrate a six-year transplant-free survival benefit in patients with ALGS using a pharmacological interventi...

- Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue - 2024 expected global net product sales of $310 million to $320 million - LIVMARLI PFIC PDUFA date on track for March 13, 2024 - Volixibat VIS...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024. Mirum will also host a conference call to discuss the fourth quarter and year-end 2023 financial results and recent corporate progress...

2024-01-31 12:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...